VEGFA and neoplasm: Anti-angiogenic therapy, particularly VEGF inhibition with bevacizumab, is a standard component of OC treatment and has been shown to modulate the TME by normalizing tumor vasculature and reducing immunosuppressive VEGF signaling [150].